WEREWOLF ®, the WEREWOLF logo, PREDATOR ®, INDUKINE ™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, ...

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

The Takeda Oncology Company. Dr. von Moltke was a practicing physician and completed a fellowship in clinical pharmacology at Tufts University School of Medicine and had an academic career in ...

3 Reasons Investors Watch United Therapeutics (UTHR) Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Check Out Our Latest Analysis on United Therapeutics United Therapeutics Stock Down 1.6 % UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week ...

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million.

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company’s revenue is heavily ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most expensive stocks insiders are dumping in March. After being in the ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...